Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironmentRuyin Chen, Jian Ruan|Cancer Cell International|2022Cited by 47
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Lin Shen, Meili Sun et al.|Nature Medicine|2025Cited by 29
FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinomaJinzhang Chen, Jian Ruan|Cancer Cell International|2020Cited by 12